Report of the 2003 Pan-Canadian Forum on Cervical Cancer Prevention and Control. The recommendations reported herein reflect the decisions of the pan-Canadian forum participants as individual experts and do not necessarily reffect official policies of their respective organizations

Journal of Obstetrics and Gynaecology Canada

Volumn 26, Issue 11, 2004, Pages 1004-1014

  Stuart, Gavin ^a   Taylor, Gregory ^b   Bancej, Christina M ^b   Beaulac, Jennifer ^b   Colgan, Terence ^c   Franco, Eduardo L ^d   Kropp, Rhonda Y ^e   Lotocki, Robert ^f   Mai, Verna ^g   Mclachlin, C Meg ^h   Onysko, Jay ^b   Martin, Ruth Elwood ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b HEALTH CANADA   (Canada)

^c MOUNT SINAI HOSPITAL   (Canada)

^d MCGILL UNIVERSITY   (Canada)

^e PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^f London Laboratory Services Group ^*  (Canada)

^g CANCER CARE ONTARIO   (Canada)

^h London Laboratory Services Group   (Canada)

Author keywords

Canada; Cervix dysplasia; Cervix neoplasms, prevention and control; Cytodiagnosis; DNA probes, HPV; Health knowledge, attitudes, practice; Mass screening; Papillomavirus infections

Indexed keywords

ARTICLE; CANADA; CANCER CONTROL; CANCER PREVENTION; CANCER SCREENING; CONCEPTUAL FRAMEWORK; CONSENSUS DEVELOPMENT; CONTROLLED CLINICAL TRIAL (TOPIC); CYTOLOGY; HEALTH CARE SYSTEM; HEALTH EDUCATION; HEALTH PROGRAM; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; LIQUID BASED CYTOLOGY; MEDICAL INFORMATION; NONHUMAN; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW (TOPIC); UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; WART VIRUS; CONFERENCE PAPER; FEMALE; MASS SCREENING; METHODOLOGY; PAPILLOMA VIRUS; PRECANCER; UTERINE CERVIX TUMOR; VAGINA SMEAR; VIRUS INFECTION;

CANADA; FEMALE; HUMANS; MASS SCREENING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PRECANCEROUS CONDITIONS; TUMOR VIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 21644442831     PISSN: 17012163     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1701-2163(16)30423-6     Document Type: Article

References (101)

1. Cervical cancer screening in Canada:. surveillance report. Ottawa 1998, 2002. Health Canada, Minister of Public Works and Government Services Canada, ON.
2. Maxwell CJ, Bancej CM, Snider J, Vik SA Factors important in promoting cervical cancer screening among Canadian women: findings from the 1996-1997 National Population Health Survey (NPHS). Can J Public Health 2001, 92(2):127-133.
3. Franco EL, Duarte-Franco E Ferenczy A Cervical cancer: epidemiology, prevention and the role of human papillomavirus infection. CMAJ 2001, 164(7):1017-1025.
4. Bohmer G, van den Brule AJ, Brummer O, Meijer CL, Petry KU No confirmed case of human papillomavirus DNA-negative cervical intraepithelial neoplasia grade 3 or invasive primary cancer of the uterine cervix among 511 patients. Am J Obstet Gynecol 2003, 189(1):118-120.
5. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, et al. Epidemiologie classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003, 348(6):518-527.
6. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV The casual relation between hu man papillomavirus and cervical cancer. J Clin Pathol 2002, 55(4):244-265.
7. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Hu man papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189(1):12-19.
8. Harro CD, Pang YY, Roden RB, Hildesheim A, Wang Z, Reynolds MJ, et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 LI virus-like particle vaccine. J Natl Cancer Inst 2001, 93(4):284-292.
9. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002, 347(21):1645-1651.
10. Noorani HZ, Brown A, Skidmore B, Stuart GCE Liquid-based cytology and human papillomavirus testing in cervical cancer screening 2003, Canadian Coordinating Office for Health Technology Assessment, Ottawa (ON).
11. Cervical cancer screening programs (Walton Report). CMAJ 1976, 114:1003-1033. Task Force on Cervical Cancer Screening Programs.
12. Cervical cancer screening programs: summary of the 1982 Canadian task force report. CMAJ 1982, 127:581-589. Task Force Convened by the Department of National Health and Weifare.
13. Miller AB, Anderson G, Brisson J, Laidlaw J, Le Pitre N, Malcolmson P, et al. Report of a national workshop on screening for cancer of the cervix. CMAJ 1991, 145(10):1301-1325.
14. Morrison BJ Screening for cervical cancer. Canadian Task Force on the Periodic Health Examination. Canadian guide to clinical preventive health care. Ottawa 1994, 870-881. ON, Health Canada.
15. Woolf SH, Battista RN, Angerson GM, Logan AG, Eel W Canadian Task Force on the Periodic Health Exam 1994, Canada Communication Group, Ottawa (ON).
16. Kish MA Guide to development of practice guidelines. Clin Infect Dis 2001, 32(6):851-854.
17. Gross PA, Barrett T, Dellinger EP, Krause PJ, Martone WJ, McGowan JE, et al. Consensus development of quality standards. Infect Control Hosp Epidemiol 1994, 15(3):180-181.
18. Wright TC, Cox JT, Massad LS, Twiggs LB, Wilkinson EJ 2001 consensus guidelines for the management of women with cervical cytological abnormalities. JAMA 2002, 287(16):2120-2129.
19. Nieminen P, Kallio M, Anttila A, Hakama M Organised vs. spontaneous Pap-smear screening for cervical cancer: a case-control study. Int J Cancer 1999, 83(1):55-58.
20. Sigurdsson K The Icelandic and Nordic cervical screening programs: trends in incidence and mortality rates through 1995. Acta Obstet Gynecol Scand 1999, 78(6):478-485.
21. European guidel ines for quality assurance in cervical cancer screening. Eur J Cancer 1993, 29A(4):S1-S38. Europe Against Cancer Programme.
22. Zapka JG, Taplin SH, Solberg LI, Manos MM A framework for improving the quality of cancer care: the case of breast and cervical cancer screening. Cancer Epidemiol Biomarkers Prev 2003, 12(1):4-13.
23. Dell DL, Chen H, Ahmad F, Stewart DE Knowledge about human papillomavirus among adolescents. Obstet Gynecol 2000, 96(5 Pt 1):653-656.
24. Ramirez JE, Ramos DM, Clayton L, Kanowitz S, Moscicki AB Genital human papillomavirus infections: knowledge, perception of risk, and actual risk in a non-clinic population of young women. J Womens Health 1997, 6(1):113-121.
25. Vaii-Smith K, White DM Risk level, knowledge, and preventive behavior for human papillomaviruses among sexually active college women. J Am Coll Health 1992, 40(5):227-230.
26. Yacobi E, Tennant C, Ferrante J, Pal N, Roetzheim R University students' knowledge and awareness of HPV. Prev Med 1999, 28(6):535-541.
27. Baer H, Allen S Braun L Knowledge of human papillomavirus infection among young adult men and women: implications for health education and research. J Community Health 2000, 25(1):67-78.
28. Waller J, McCaffery K, Forrest S, Szarewski A, Cadman L, Wardle J Awareness of human papillomavirus among women attending a weil woman di nic. Sex Transm Infect 2003, 79(4):320-322.
29. Pitts M, Clarke T Human papillomavirus infections and risks of cervical cancer:what do women know?. Health Educ Res 2002, 17(6):706-714.
30. Clark LR, Jackson M, Allen-Taylor L Adolescent knowledge about sexually transmitted diseases. Sex Transm Dis 2002, 29(8):436-443.
31. Sellors JW, Mahony J B, Kaczorowski J, Lytwyn A, Bangura H, Chong S, et al. Prevalence and predictors of human papillomavirus infection in women in Ontario, Canada. Survey of HPV in Ontario Women (SHOW) Group. CMAJ 2000, 163(5):503-508.
32. Chan PK, Chang AR, Cheung JL, Chan DP, Xu LY, Tang NL, et al. Determinants of cervical human papillomavirus infection: differences between high- and low-oncogenic risk types. J Infect Dis 2002, 185(1):28-35.
33. Kjaer SK, Chackerian B, van den Brule AJ, Svare EL, Pauli G, Pauli G, Walbomers JM, et al. High-risk human papillomavirus is sexually transmitted: evidence from a follow-up study of virgins starting sexual activity (intercourse). Cancer Epidemiol Biomarkers Prev 2001, 10(2):101-106.
34. Ludicke F, Stalberg A, Vassilakos P, Major AL, Campana A High- and intermediate-risk human papillomavirus infection in sexually active adolescent females. J Pediatr Adolesc Gynecol 2001, 14(4):171-174.
35. Franco EL, Villa LL, Ruiz A, Costa MC Transmission of cervical human papillomavirus infection by sexual activity: differences between low and high oncogenic risk types. J Infect Dis 1995, 172(3):756-763.
36. Silins I, Kallings I, Dillner J Correlates of the spread of human papillomavirus infection. Cancer Epidemiol Biomarkers Prev 2000, 9(9):953-959.
37. Rousseau MC, Franco EL, Villa LL, Sobrinho JP, Termini L, Prado JM, et al. A cumulative case-control study of risk factor profiles for oncogenic and non-oncogenic cervical human papillomavirus infections. Cancer Epidemiol Biomarkers Prev 2000, 9(5):469-476.
38. Burk RD, Ho GY, Beardsley L, Lempa M, Peters M, Bierman R Sexual behavior and partner characteristics are the predominant risk factors for genital human papillomavirus infection in young women. J Infect Dis 1996, 174(4):679-689.
39. Manhart LE, Koutsky LA Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia1 A meta-analysis. Sex Transm Dis 2002, 29(11):725-735.
40. Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003, 157(3):218-226.
41. McCaffery K, Forrest S, Waller J, Desai M, Szarewski A, Wardle J Attitudes towards HPV testing: a qualitative study of beliefs among lndian, Pakistani, African-Caribbean and white British women in the UK. Br J Cancer 2003, 88(1):42-46.
42. Biro FM, Rosenthal SL, Rymarquis L, Kollar LM, Hillard PJ Adolescent girls' understanding of Papanicolaou smear results. J Pediatr Adolesc Gynecol 1997, 10(4):209-212.
43. Braun V, Gavey N Exploring the possibility of sexual-behavioural primary prevention interventions for cervical cancer. Aust N Z J Public Health 1998, 22(3 Suppl):353-359.
44. Helmerhorst TJ, Meijer CJ Cervical cancer should be considered as a rare complication of oncogenic HPV infection rather than an STD. Intj Gynecol Cancer 2002, 12(3):235-236.
45. Lambert EC College students' knowledge of human papillomavirus and effectiveness of a brief educational intervention. J Am Board Fam Pract 2001, 14(3):178-183.
46. Shepherd J, Peersman G, Weston R, Napuli I Cervical cancer and sexual lifestyle: a systematic review of health education interventions targeted at women. Health Educ Res 2000, 15(6):681-694.
47. National Institute for Clinical Excellence. Appraisal consultation document: guidance on the use of liquid-based cytology for cervical screening (review of existing guidance number 5). Available on-line at . Accessed May 29, 2003.
48. Payne N, Chilcott J, McGoogan E Liquid-based cytology in cervical screening: a rapid and systematic review. Health Technol Assess 2000, 4(18):1-73.
49. Klinkhamer PJ, Meerding WJ, Rosier PF, Hanselaar AG Liquid-based cervical cytology. Cancer 2003, 99(5):263-271.
50. Kim JJ, Wright TC, Goldie SJ Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance. JAMA 2002, 287(18):2382-2390.
51. Saslow D, Runowicz CD, Solomon D, Moscicki AB, Smith RA, Eyre HJ, et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin 2002, 52(6):342-362.
52. Hutchinson ML, Agarwal P, Denault T, Berger B, Cibas ES.A new look at cervical cytology. ThinPrep multicenter trial results. Acta Cytol 1992, 36(4):499-504.
53. Hoelund B Implementation of liquid-based cytology in the screening programme against cervical cancer in the County of Funen, Denmark, and status for the first year. Cytopathology 2003, 14(5):269-274.
54. Broadstock M Effectiveness and cost effectiveness of automated and semi-automated cervical screening deviees: a systematic review of the literature. N Z Med J 2001, 114(1135):311-313.
55. Scottish Cervical Screening Programme: Steering group report on the feasibility of introducing liquid based cytology. January 2002. Available on-line at . Accessed June 4, 2003.
56. Franco EL Chapter 13: primary screening of cervical cancer with human papillomavirus tests. J Natl Cancer Inst Monogr 2003, 31:89-96.
57. Belinson J, Qiao YL, Pretorius R, Zhang WH, Elson P, Li L, et al. Shanxi Province Cervical Cancer Screening Study: a cross-sectional comparative trial of multiple techniques to detect cervical neoplasia. Gynecol Oncol 2001, 83(2):439-444.
58. Salmeron J, Lazcano-Ponce E, Lorincz A, Hernandez M, Hernandez P, Leyva A, et al. Comparison of HPV-based assays with Papanicolaou smears for cervical cancer screening in Morelos State, Mexico. Cancer Causes Control 2003, 14(6):505-512.
59. Cuzick J, Szarewski A, Terry G, Ho L, Hanby A, Maddox P, et al. Human papillomavirus testing in primary cervical screening. Lancet 1995, 345(8964):1533-1536.
60. Cuzick J, Beverley E, Ho L, Terry G, Sapper H, Mielzynska I, et al. HPV testing in primary screening of older women. Br J Cancer 1999, 81(3):554-558.
61. Kuhn L, Denny L, Pollack A, Lorinez A, Richart RM, Wright TC, Human Papillomavirus DNA testing for cervical cancer screening in low-resource settings. J Natl Cancer Inst 2000, 92(10):818-825.
62. Clavel C, Masure M, Bory JP, Putaud I, Mangeonjean C, Lorenzato M, et al. Hybrid capture II-based human papillomavirus detection, a sensitive test to detect in routine high-grade cervical lesions: a preliminary study on 1518 women. Br J Cancer 1999, 80(9):1306-1311.
63. Clavel C, Masure M, Bory JP, Putaud I, Mangeonjean C, Lorenzato M, et al. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br J Cancer 2001, 84(12):1616-1623.
64. Blumenthal PD, Gaffikin L, Chirenje ZM, McGrath J, Womack S, Shah K Adjunctive testing for cervical cancer in low-resource settings with visual inspection, HPV, and the Pap smear. Int J Gynaecol Obstet 2001, 72(1):47-53.
65. Petry KU, Scholz U, Hollowitz B, Von-Wasielewski R, Meijer CJ Inclusion of HPV testing in routine cervical cancer screening for women above 29 in Germany: results for 8466 patients. Br J Cancer 2003, 88(10):1570-1577.
66. Schneider A, Hoyer H, Lotz B, Leistritza S, Kuhne-Heid R, Nindl L, et al. Screening for high-grade cervical intra-epithelial neoplasia and cancer by testing for high-risk HPV, routine cytology or colposcopy. Int J Cancer 2000, 89(6):529-534.
67. Kulasingam SL, Hughes JP, Kiviat NB, Mao C, Weiss NS, Kuypers JM, et al. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA 2002, 288(14):1749-1757.
68. Womack SD, Chirenje ZM, Gaffikin L, Blumenthal PD, McGrath JA, Chipato T, et al. HPV-based cervical cancer screening in a population at high risk for HIV infection. Int J Cancer 2000, 85(2):206-210.
69. Schiffman M, Herrero R, Hildesheim A, Sherman ME, Bratti M, Wacholder S, et al. HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica. JAMA 2000, 283(1):87-93.
70. Ratnam S, Franco EL, Ferenczy A Human papillomavirus testing for primary screening of cervical cancer precursors. Cancer Epidemiol Biomarkers Prev 2000, 9(9):945-951.
71. Wright TC, Denny L, Kuhn L, Pollack A, Lorincz A HPV DNA testing of self-collected vaginal samples compared with cytologie screening to detect cervical cancer. JAMA 2000, 283(1):81-86.
72. Coste J, Cochand-Priollet B, de Cremoux P, Le Gales C, Cartier I, Molinie V, et al. Cross-sectional study of conventional cervical smear, monolayer cytology, and human papillomavirus DNA testing for cervical cancer screening. Br Med J 2003, 326(7392):733.
73. Bory JP, Cucherousset J, Lorenzato M, Gabriel R, Quereux C, Birembaut P, et al. Recurrent human papillomavirus infection detected with the hybrid capture II assay selects women with normal cervical smears at risk for developing high-grade cervical lesions: a longitudinal study of 3,091 women. lnt J Cancer 2002, 102(5):519-525.
74. Molano M, Van den Brule A, Plummer M, Weiderpass E, Posso H, Arslan A, et al. Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study. Am J Epidemiol 2003, 158(5):486-494.
75. Schlecht NF, Kulaga S, Robitaille J, Ferreira S, Santos M, Miyamura RA, et al. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA 2001, 286(24):3106-3114.
76. Sherman ME, Lorincz AT, Scott DR, Wacholder S, Castle PE, Glass AG, et al. Baseline cytology, hu man papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst 2003, 95(1):46-52.
77. Kjaer SK, van den Brule AJ, Pauli G, Svare EL, Sherman ME, Thomsen BL, et al. Type-specific persistence of high-risk hu man papillomavirus (HPV) as indicator of high-grade cervical squamous intraepithelial lesions in young women: population-based prospective follow-up study. Br Med J 2002, 325(7364):572.
78. Goldie SJ, Freedberg KA, Weinstein MC, Wright TC, Kuntz KM Cost effectiveness of human papillomavirus testing to augment cervical cancer screening in women infected with the human immunodeficiency virus. Am J Med 2001, 111(2):140-149.
79. Goldie SJ, Kim JJ, Wright TC Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more. Obstet Gynecol 2004, 103(4):619-631.
80. Young TK, McNicol P, Beauvais J Factors associated with human papillomavirus infection detected by polymerase chain reaction among urban Canadian aboriginal and non-aboriginal women. Sex Transm Dis 1997, 24(5):293-298.
81. Richardson H, Franco E, Pintos J, Bergeron J, Arella M, Tellier P Determinants of low-risk and high-risk cervical human papillomavirus infections in Montreal University students. SexTransm Dis 2000, 27(2):79-86.
82. Rohan T, Mann V, Mclaughlin J, Harnish DG, Yu H, Smith D, et al. PCR-detected genital papillomavirus infection: prevalence and association with risk factors for cervical cancer. Intj Cancer 1991, 49(6):856-860.
83. Ferenczy A, Gelfand MM, Franco E, Mansour N Human papillomavirus infection in postmenopausal women with and without hormone therapy. Obstet Gynecol 1997, 90(1):7-11.
84. Healey SM, Aronson KJ, Mao Y, Schlecht NF, Mery LS, Ferenczy A, et al. Oncogenic human papillomavirus infection and cervical lesions in aboriginal women of Nunavut, Canada. Sex T ransm Dis 2001, 28(12):694-700.
85. Sellors JW, Karwalajtys TL, Kaczorowski JA, Mahony JB, Lytwyn A, Chong S, et al. Prevalence of infection with carcinogenic human papillomavirus among older women. CMAJ 2002, 167(8):871-873.
86. Baay MF, Smits E, Tjalma WA, Lardon F, Weyler J, Van Royen P, et al. Can cervical cancer screening be stopped at 50? the prevalence of HPV in elderly women. Int J Cancer 2004, 108(2):258-261.
87. Hopman EH, Rozendaal L, Voorhorst FJ, Walboomers JM, Kenemans P, Helmerhorst TJ High risk human papillomavirus in women with normal cervical cytology prior to the development of abnormal cytology and colposcopy. Br J Obstet Gynaecol 2000, 107(5):600-604.
88. Cuzick J, Szarewski A, Cubie H, Hulman G, Kitchener H, Luesley D, et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet 2003, 362(9399):1871-1876.
89. Anhang R, Wright TC, Smock L, Goldie SJ Women's desired informati on about human papillomavirus. Cancer 2004, 100(2):315-320.
90. Philips Z, Johnson S, Avis M, Whynes DK Human papillomavirus and the value of screening: young women's knowledge of cervical cancer. Health Educ Res 2003, 8(3):318-328.
91. McCaffery K, Forrest S, Waller J, Desai M, Szarewski A, Wardle J Attitudes towards HPV testing: a qualitative study of beliefs among lndian, Pakistani, African-Caribbean and white British women in the UK. Br J Cancer 2003, 88(1):42-46.
92. Solomon D, Schiffman M, Tarone R Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst 2001, 93(4):293-299.
93. Manos MM, Kinney WK, Hurley LB, Sherman ME, Shieh-Ngai J, Kurman RJ, et al. Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results. JAMA 1999, 281(17):1605-1610.
94. Bergeron C, Jeannel D, Poveda J, Cassonnet P, Orth G Human papillomavirus testing in women with mild cytologie atypia. Obstet Gynecol 2000, 95(6 Pt 1):821-827.
95. Ferris DG, Wright TC, Litaker MS, Richart RM, Lorincz AT, Sun XW, et al. Triage of women with ASC-US and LSIL on Pap smear reports: management by repeat Pap smear. HPV DNA testing, or colposcopy1 J Fam Pract 1998, 46(2):125-134.
96. Cox JT, Lorinez AT, Schiffman MH, Sherman ME, Culien A, Kurman RJ Human papillomavirus testing by hybrid capture appears to be useful in triaging women with a cytologie diagnosis of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 1995, 72(3):946-954.
97. Lytwyn A, Sellors JW, Mahony JB, Daya D, Chapman W, Ellis N, et al. Comparison of human papillomavirus DNA testing and repeat Papanicolaou test in women with low-grade cervical cytologie abnormalities: a randomized trial. HPV Effectiveness in Lowgrade Paps (HELP) Study No.l Group. CMAJ 2000, 163(6):701-707.
98. Arbyn M, Buntinx F, Van Ranst M, Paraskevaidis E, Martin-Hirsch P, Dillner J Virologic versus cytologie triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J Natl Cancer Inst 2004, 96(4):280-293.
99. Mclachlin CM, Alanen KW, Elit LM, Smith EA, Kerkvliet NA Hybrid capture human papillomavirus testing as an adjunct to the follow-up of patients with ASC-US and LGSIL Pap smears: a study of a screening population. J Lower Genital Tract Dis 2000, 4(1):12-17.
100. Lytwyn A, Sellors JW, Mahony JB, Daya D, Chapman W, Howard M, et al. Adjunctive human papillomavirus testing in the 2-year follow-up of women with low-grade cervical cytologie abnormalities: a randomized trial and economie evaluation. Arch Pathol Lab Med 2003, 127(9):1169-1175.
101. Munoz N, Bosch F, Castellsagué X, Diaz M, de San Jose S, Hammouda D, et al. Against which human papillomavirus types shall we vaccinate and screen1 the international perspective. Int J Cancer. press 2004.